- Home
- INSM vs FTV Comparison
INSM vs FTV Comparison
Compare INSM & FTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- FTV
- Stock Information
- Founded
- INSM 1988
- FTV 2015
- Country
- INSM United States
- FTV United States
- Employees
- INSM N/A
- FTV N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- FTV Industrial Machinery/Components
- Sector
- INSM Health Care
- FTV Industrials
- Exchange
- INSM Nasdaq
- FTV Nasdaq
- Market Cap
- INSM 29.0B
- FTV 23.9B
- IPO Year
- INSM 2000
- FTV N/A
- Fundamental
- Price
- INSM $189.60
- FTV $50.34
- Analyst Decision
- INSM Strong Buy
- FTV Hold
- Analyst Count
- INSM 19
- FTV 13
- Target Price
- INSM $171.12
- FTV $60.17
- AVG Volume (30 Days)
- INSM 2.1M
- FTV 2.7M
- Earning Date
- INSM 10-30-2025
- FTV 10-29-2025
- Dividend Yield
- INSM N/A
- FTV 0.47%
- EPS Growth
- INSM N/A
- FTV N/A
- EPS
- INSM N/A
- FTV 1.75
- Revenue
- INSM $447,022,000.00
- FTV $6,260,300,000.00
- Revenue This Year
- INSM $32.08
- FTV N/A
- Revenue Next Year
- INSM $125.86
- FTV $3.25
- P/E Ratio
- INSM N/A
- FTV $19.52
- Revenue Growth
- INSM 30.34
- FTV 36.34
- 52 Week Low
- INSM $60.40
- FTV $45.51
- 52 Week High
- INSM $197.08
- FTV $62.79
- Technical
- Relative Strength Index (RSI)
- INSM 76.69
- FTV 55.99
- Support Level
- INSM $154.79
- FTV $48.98
- Resistance Level
- INSM $168.22
- FTV $55.93
- Average True Range (ATR)
- INSM 6.44
- FTV 1.40
- MACD
- INSM 1.81
- FTV 0.17
- Stochastic Oscillator
- INSM 82.31
- FTV 29.95
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
About FTV Fortive Corporation
Fortive is a diversified industrial technology firm with a broad portfolio of mission-critical products and services that include field solutions, product realization, health, and sensing technologies. The company serves a wide range of end markets, including manufacturing, utilities, medical, and electronics. Fortive generated roughly $6.2 billion in revenue in 2024.